The Vytonic Respiratory Nano-silver Collaboration (RNC) is a drug development open-source program. While there has been good academic research done on the anti-bacterial and anti-viral potential of nano-silver colloids (NAgC), there has not been any proper drug development program or progress done. Consequently, the commercial market has been left to be filled by unprofessional manufacturers and unsupported medical claims. According to our analysis (see our “scientific background”), non of the products on the market is effective for medical treatment. Moreover, we proclaim that the proper medicinal application of colloidal silver for respiratory care is by inhalation (not by ingestion). The Vytonic Respiratory Nano-silver Collaboration (RNC) is established in order to decisively change this state of affairs in the world. Our goal is to proceed through all the steps and procedures of drug development as suitable anywhere in the world. The RNC will guide and provide:

• Standardized formulations – free for any R&D, testing and clinical trials
• Funding assistance to research and clinical trials
• Regulatory support
• Open channels to manufacturing resources

The Vytonic COVID-19 Respiratory Nano-silver Collaboration (RNC) is an initiative that brings together academia, national institutions, healthcare providers, technology firms, nonprofits, and startups. Together, we shall develop and promote public non-proprietary (non-patented) pharmaceutical formulations, based on Nano-silver colloids, for treatments of respiratory infections via inhalation delivery. These formulations should enable the improvement of public health and hospital intensive care outcomes, at a low cost that can be globally accessible and available within a short duration. Our main target treatment areas comprise: (a) Corona (SARS) viral infections, (b) Influenza, and (c) hospital ventilator associated pneumonia (VAP). We will endeavour to develop standardized formulations, through clinical trials, all the way to medicinal regulatory approval in any country in the world.

Respiratory infections, ranging from Influenza, to SARS, and to hospital acquired pneumonia, are a constant devastating threat to public health and hospital patients worldwide. Nano-silver colloids (NAgC) have overwhelmingly positive in-vitro and animal testing data, combined with similarly established strong and diverse safety testing (both academic and EU and USA national safety bodies reviews). If it was some other new drug substance, it would have been heralded as one of the most promising anti-microbial potential drugs in history, which would have been rushed to be developed by big pharma companies. That this did not happen, with nano-silver colloids, is only due to a market failure – the inability to patent any of it. Consequently, the gap between promising academic research and marketable regulatory approved products has been filled by “alternative medicine” unprofessional charlatans – giving bad publicity to the whole field. In order to overcome this market failure situation, we here establish our open-source drug development program – the Respiratory Nano-silver Collaboration (RNC). Our goal is to realise the potential of nano-silver colloids to deliver effective, safe and globally affordable respiratory infections treatments.

 Pharmaceuticals

 Biotechnology

 Nanotechnology and Nanosciences

 Clinical trials